On one hand, these agents are currently being explored for their efficacy in other tumor types; on the other hand, the molecular mechanisms of CXCR4 in thyroid cancer remain to be elucidated, necessitating further in-depth studies in the future. This evidence concerns the gene CXCR4 and thyroid gland carcinoma.